[1] 张春宁, 林华明, 麦大海, 等. 肝动脉化疗栓塞术治疗中晚期原发性肝癌及预后相关因素分析. 肝脏, 2018, 23:229-231.
[2] Cordie A, Salama A, El-Sharkawy M, et al. Comparing the efficiency of Fib-4, Egy-score, APRI and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. J MED VIROL, 2018, 90:1106-1111.
[3] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肝胆病杂志, 2011, 20:929-946.
[4] Nishikawa H, Osaki Y, Komekado H, et al. Clinical significance of the FIB-4 index for non-B non-C hepatocellular carcinoma treated with surgical resection. ONCOL REP, 2015, 33:88-94.
[5] 王梅, 尉从新, 杨贵华,等. 肝硬化CT分级评估肝癌介入治疗肝储备功能及预后的临床价值. 中国老年学杂志, 2017, 37:2197-2198.
[6] 徐佳, 王萱, 金征宇. 增强MRI定量评价肝纤维化及肝功能的研究进展. 中华放射学杂志, 2016, 50:994-996.
[7] Kim W R, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J HEPATOL, 2016, 64:773-780.
[8] Merli M, Galli L, Castagna A, et al. Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients. NEW MICROBIOL, 2016, 39:110-113.
[9] Qiang L, Lu C, Li W, et al. Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. ONCOTARGET, 2017, 8:45768-45776. |
